Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NTRK1 fusion |
| Therapy | Larotrectinib |
| Indication/Tumor Type | spindle cell sarcoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK1 fusion | spindle cell sarcoma | predicted - sensitive | Larotrectinib | Case Reports/Case Series | Actionable | In a Phase II trial (ADVL1823), first-line Vitrakvi (larotrectinib) treatment resulted in an objective response rate of 60% (9/15), 2-year event-free survival of 80%, and 2-year overall survival rate of 93.3% in patients with NTRK-rearranged solid tumors, including 5 partial responses in 7 patients with spindle cell neoplasm harboring NTRK1 fusion (n=4) or NTRK3 fusion (n=3) (PMID: 39652801; NCT03834961). | 39652801 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39652801) | Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). | Full reference... |